Purpose Of Review: The occurrence of pediatric venous thromboembolism (VTE) and the associated sequelae are increasing. The purpose of this PubMed-based review was to summarize the evidence published between 1 August 2014 and 31 March 2015 regarding pediatric VTE epidemiology, risk factors and risk scores, as well as the results from clinical prevention and treatment studies in children. We also sought to provide an update regarding ongoing clinical trials in pediatric VTE prevention and treatment, based on a recent (31 March 2015) search of the clinicaltrials.gov and EudraCT clinical trial registration databases.
Recent Findings: Recent research has defined and/or substantiated risk factors and risk models for pediatric VTE. Studies of pharmacokinetics/pharmacodynamics and safety/efficacy of fondaparinux and dalteparin have also been reported, in addition to findings of the pilot/feasibility phase of a randomized controlled trial on duration of anticoagulation. With regard to oral direct anticoagulants, to date 14 pediatric clinical trials have been registered on clinicaltrials.gov and EudraCT, some of which represent US/North American instances of trials previously launched in Europe.
Summary: The present findings on published studies and registered trials in pediatric VTE mark an ongoing period of remarkable activity and advancement in the field of pediatric VTE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOH.0000000000000168 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Massive pulmonary thromboembolism in a pediatric patient with eosinophilic granulomatosis with polyangiitis: a case-based review emphasizing management.
Pediatr Rheumatol Online J
January 2025
Department of Pediatric Rheumatology, Faculty of Medicine, Gazi University, Ankara, Besevler, 06500, Turkey.
Background: Pediatric patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) are at an increased risk of arterial and venous thromboembolism (AVTE). Although the exact mechanisms underlying AVTE remain unclear, eosinophils play a pivotal role in AVTE.
Main Body: Current guidelines lack evidence-based recommendations, particularly concerning anticoagulant and antiplatelet treatments for this condition.
Molecular signatures associated with venous thromboembolism in children with acute lymphoblastic leukemia.
J Thromb Haemost
December 2024
Department of Pediatrics, Centre Hospitalier Universitaire de Québec - Centre Mère-Enfant Soleil, Quebec City, Quebec, Canada; Centre de Recherche du Centre Hospitalier Universitaire de Québec, Quebec City, Quebec, Canada. Electronic address:
Background: Venous thromboembolism (VTE) is a frequent complication of childhood acute lymphoblastic leukemia (ALL).
Objectives: We aimed to identify molecular markers and signatures of leukemia microenvironment associated with VTE in childhood ALL, by dual-omics approach of gene expression (GEP) and DNA-methylation profiling.
Patients/methods: Eligible children were aged 1-21 years old with newly diagnosed ALL enrolled on the Dana Farber Cancer Institute 16-001 trial with available RNA sequencing data from bone marrow at diagnosis.
Assessment of a next generation sequencing gene panel strategy in 133 patients with negative thrombophilia screening.
J Thromb Haemost
December 2024
C2VN, INSERM, INRAE, Aix Marseille University, Marseille, France; Laboratory of Haematology, La Timone Hospital, Marseille, France. Electronic address:
Background: Although heritability of venous thromboembolism (VTE) is high, the thrombophilia screening appears to be positive only in a minority of VTE patients. Adding rare variants screening to identify VTE missing heritability still requires further assessment.
Objectives: We report the results of a panel strategy after 3 years of application.
Update on Cancer-Associated Venous Thromboembolism in Children.
Hamostaseologie
December 2024
Department of Oncology, Hematology, Immunology, Stem Cell Transplantation and Somatic Gene Therapy, University Children's Hospital Zurich - Eleonore Foundation, Zurich, Switzerland.
Children with cancer have an increased risk for venous thromboembolic events (VTEs) compared to the healthy pediatric population. VTE rates in children with cancer vary among cancer types. Other VTE risk factors include central venous catheters and cancer therapies.
View Article and Find Full Text PDFUnresolved issues concerning venous thromboembolism. Venous thromboembolism in children. Consensus of the French Society of Vascular Medicine (SFMV).
J Med Vasc
December 2024
Vascular Medicine Department, Toulouse University Hospital, Toulouse, France.
Venous thromboembolism (VTE) rarely occurs during childhood and, with few exceptions, should be considered as a disease of sick children. Current recommendations concerning the duration of anticoagulant treatment for paediatric VTE are essentially based on the results of clinical trials conducted in adults. Yet the underlying medical conditions, incidence, and anatomical locations of the disease, as well as the rates of unprovoked VTE, morbidity, and mortality, differ between adults and children.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!